BA
CLVS

BlackRock Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

BlackRock Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-500
Closed -$18K – 3829
2015
Q4 		$18K Buy
+500
New +$32.2K ﹤0.01% 3520

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Advisors's CLVS Position: Q4 2016 in Review

BlackRock Advisors increased its Clovis Oncology, Inc. (CLVS) stake by 24% in Q4 2016, buying an estimated $412K and bringing the position to 60,785 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1377.

BlackRock Advisors first reported a position in CLVS in Q2 2013 and has held it in 15 quarters since. The position peaked at $24.2M in Q3 2015. 167 funds tracked by Wall St. Rank hold CLVS as of Q4 2016.

  • BlackRock Advisors held 60,785 shares of Clovis Oncology, Inc. worth $2.7M as of Q4 2016.
  • BlackRock Advisors bought 11,692 Clovis Oncology, Inc. shares in Q4 2016, an estimated $412K.
  • Clovis Oncology, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1377 holding.
  • BlackRock Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Clovis Oncology, Inc. position peaked at $24.2M in Q3 2015.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.